Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Infusion · 1 trial · 1 indication
Assessment of total radioactivity by measuring AZD7594 excreted (Ae)
Assessment of total radioactivity by measuring AZD7594 excreted and expressed as a percentage of the administered dose (Fe)
Assessment of total radioactivity by measuring the cumulative amount of AZD7594 excreted (CumAe)
Assessment of total radioactivity by measuring AZD7594 excreted and expressed as a percentage of the administered dose (CumFe)
Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry
Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry
Assessment of metabolites and structural identification by assessing liquid chromatography-radiochemical-detection and subsequent mass spectrometry
| Arm | Type | Description |
|---|---|---|
| Only one study arm | EXPERIMENTAL | \[14C\]AZD7594 Solution for Infusion 5 µg/mL (1.1 kBq/mL) AZD7594 Inhalation Powder, SD3FL Inhaler |
| Name | Type | Description |
|---|---|---|
| Intravenous Infusion | DRUG | 30 µg \[14C\]AZD7594 containing 6.7 kBq (180 nCi) carbon-14 (14C) as a 1 hour infusion. |
| Inhaled dose | DRUG | A single inhalation on one occasion. |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male or non-pregnant, non-lactating female subjects aged 18 to 55 years with suitable veins for cannulation or repeated venepuncture. 3. Have a body mass index of 18.5 t...
Infusion is an investigational small molecule being developed by AstraZeneca for the treatment of asthma. It is currently in Phase 1 clinical development, meaning it has not yet been approved for any use. The drug is being studied to understand its pharmacokinetics and metabolism in the body.
Infusion is being developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker symbol AZN. AstraZeneca is conducting clinical trials to evaluate the safety and pharmacokinetics of this investigational drug for asthma.
Infusion is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials. The Phase 1 trial for Infusion has been completed, and the drug remains in early-stage development for asthma.
Infusion has one completed Phase 1 clinical trial registered under NCT04002427, titled "Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594." The trial enrolled 6 participants with asthma in the United Kingdom and was an uncontrolled, non-randomized study.
Yes, Infusion is also known as AZD7594. The clinical trial NCT04002427 for Infusion is titled "Mass Balance Recovery, Pharmacokinetics and Metabolite Profile and Identification of [14C]AZD7594," confirming that AZD7594 is the alternative name for this investigational drug being developed by AstraZeneca.